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Ia antigens are a class of cell surface glycoproteins encoded within the murine major 
histocompatibility complex  (MHC) 1 that  have a  characteristic  molecular structure 
and tissue distribution.  The genetics, structure,  and function of these molecules are 
being investigated intensively because Ia antigens have been found to be involved in 
antigen recognition by T lymphocytes and are believed to regulate antigen recognition 
by those T  lymphocytes (1, 2). In man, HLA-DR is the only Ia-like molecule that has 
been well characterized with respect to:  (a) determination of its molecular structure; 
(b)  mapping the gene that  encodes  it;  and  (c)  assigning it  a  role in  human  T  cell 
recognition  (3-5).  However, multiple lines of evidence indicate that there is at least 
one other, and perhaps many more, human Ia-like gene products. This complexity is 
evident from serologic (6-9) and immunochemical (10-19) analyses; however, little is 
known about the ability of these determinants to function in T  cell recognition  (20), 
and the available genetic data  (7,  21)  are insufficient  to conclusively establish  that 
these determinants are controlled by genes distinct from HLA-DR. Such correlations 
between structure, genetics, and function will have to be established to achieve a more 
general understanding of human Ia antigens. 
Recently, cellular typing reagents were developed that defined five alleles of a new 
segregant  series of secondary B  cell  (SB)  antigens  (22,  23);  they were shown  to  be 
encoded  by an HLA-linked locus that was distinguished  from HLA-DR  by identifi- 
cation  of recombinant  families  (24)  and  studies  of mutant  cell  lines  (25).  It  was 
hypothesized on the basis of function and tissue distribution that the SB gene product 
is an h-like molecule (22).  Independently, a monoclonal antibody was identified  (18, 
26)  that reacted with an antigen whose molecular structure was similar to HLA-DR, 
but that could be distinguished  from the HLA-DR molecule by sequential immuno- 
precipitation.  One relatively unique characteristic of ILR1 reactivity and of the SB 
antigens  made  it  plausible  that  both  might  relate  to  the  same  genetic  system-- 
although  each was encoded  by a  locus  linked  to HLA-DR,  in  neither  case did  the 
* Supported in part by grant AI-15486 from the National Institutes of Health. 
l Abbreviations used in this paper." FMF, flow microfluorometry; LCL, lymphoblastoid cell line; MHC, 
major histocompatitibility  complex; SB, secondary B cell. 
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polymorphism correlate well with HLA-DR  in the population. 
Three  lines  of evidence  described  in  this  report  indicate  that  this  monoclonal 
antibody, ILR1, reacts with  at  least two  allelic forms of the SB molecule:  SB2  and 
SB3. This evidence, combined with  previous structural studies of the ILRl-reactive 
molecule, indicates that the SB gene product has the structure of an Ia-like molecule. 
Furthermore,  the serologic analysis of HLA  mutant  cell lines with  this monoclonal 
antibody supports the inference made from previous studies using cellular typing (24, 
27, 28) that there are two HLA regions centromeric to HLA-B that control expression 
of Ia-like molecules:  a  region toward  HLA-B  that  controls expression of HLA-DR, 
and  a  region  toward  GLO  that  controls  expression  of SB.  These  data  provide  an 
initial correlation between a triad of findings: the SB antigens function as immunogens 
in human cellular immune responses, they are encoded by a  locus in the HLA region 
that is distinct from HLA-DR, and they are present on an Ia-like molecule. Thus, SB, 
like HLA-DR, appears to be a  human  equivalent of the  murine  Ia  molecules, and 
may therefore be important in regulation of human  immune responses. 
Materials  and  Methods 
Monoclonal Antibodies.  Murine monoclonal antibodies I2, ILR1 (18, 26), and L227 (29) were 
grown in vitro or as ascites as previously described. The reactivity of cells with monoclonal 
antibodies was analyzed by indirect immunofluorescence measured by flow microfluorometry 
(FMF)  using  a  fluorescence-activated cell  sorter  (FACS  II,  B-D  FACS  Systems,  Becton, 
Dickinson  &  Co.,  Sunnyvale,  CA)  as  described  (30,  31).  To  optimize comparison  of data 
collected at different linear electronic amplifications, fluorescence units (adjusted to gain  16) 
were calculated according to the formula: FU =  (median fluorescence channel  -  10)  ×  16/ 
gain.  The  measurement  of fluorescence  units  from  cells  incubated  in  the  presence  of the 
monoclonal antibody followed by fluorescent reagent [goat F(ab')2 anti-mouse IgG(H+L), N. 
L. Cappel Laboratories, Cochraneville, PAl was corrected by subtraction of fluorescence units 
measured on the same cell population incubated with the fluorescent reagent alone. All reagents 
were pretested and subsequently used at saturating concentrations. Cells were scored as ILR 1- 
negative if they had  <40  fluorescent units  of binding;  all ILRl-positive donors  had  >150 
fluorescent units of binding. 
Cellular Studies.  Primed lymphocyte typing for SB antigens was performed as previously 
described on peripheral blood mononuclear cells (23) and lymphoblastoid B cell lines (LCL) 
(25);  serotyping of cells for DR antigens was kindly performed by Dr. R. Duquesnoy  (Blood 
Center of Southeastern Wisconsin, Milwaukee, WI) using the standard National Institutes of 
Health  (NIH) lymphocytotoxicity technique on peripheral blood B cells. LCL for the panel 
studies were established from peripheral blood lymphoeytes using Epstein-Barr virus transfor- 
mation as previously described (32).  For antibody inhibition of proliferation, the routine 3-d 
primed lymphocyte-typing assay (23)  was modified as follows. Ascites was diluted  1:25  into 
medium (RPMI  1640 with glutamine [Grand Island Biological Co., Grand Island, NY] with 
added penicillin [10 U/ml], streptomycin [10/~g/ml], and 15% heat-inactivated normal pooled 
human heparinized plasma). Diluted ascites or undiluted culture supernatant (25 #1) was added 
to flat-bottomed microtiter plates. Responder cells (2 X  104) and irradiated peripheral blood 
mononuclear stimulator cells (1  ×  105) were  each  added  in  25 #1  of media.  Cultures  were 
established in triplicate and results are expressed as the geometric mean cpm of [3H]thymidine 
incorporation. 
Mutant Cell Lines.  Cloned mutant cell lines were established using gamma irradiation and 
serologic negative selection according to the general procedures previously described (33).2 The 
"DR-null" mutants  were derived by negative selection from  a  mutant  line  (721.45.1)  from 
2 R. DeMars, C. Chang, R. Rudersdorf, and H. T. Orr. Dissection of the human major histocompatibility 
complex with gamma ray-induced mutations  in lymphoblastoid cells. Manuscript submitted for publica- 
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which  an  entire  HLA  haplotype  had  been  physically  deleted.  A  DR-specific  monoclonal 
antibody  L243  (29)  was  used  to  isolate  DR-null  mutants  after  gamma  irradiation  of line 
721.45.1.  The  resulting  mutants  had  lost  expression  of cell  surface  molecules  detectable  by 
antibody L243. 
Statistics and Nomenclature.  Overall statistical correlations of DR or SB and ILR 1 reactivity 
were made using chi-square analysis.  Comparisons of individual  DR  or SB alleles and  ILR1 
reactivity were made using the Fisher's exact  test.  Standard  conventions have  been used  for 
genetic nomenclature  (34). 
Results 
Population  Studies  of  the  Association  between ILR1  Reactivity  and  HLA-DR  and 
SB.  Original  characterization of the  ILR1  antibody indicated  that  it  detected a 
polymorphism which did not correlate with HLA-DR in the Caucasian  population 
(18, 26). FMF analysis of the binding of ILR1 to our panel of 47 LCL (Table I):  (a) 
demonstrates that ILR1  reactivity was observed with 66% of our cells;  (b) confirms 
the lack of overall association with HLA-DR phenotype (P =  0.33); (c) demonstrates 
a strong overall association between cells' reactivity with ILR 1 and their SB phenotype 
(P <  0.003). These findings strongly suggest that ILR 1 might recognize determinants 
related to SB, but also demonstrate that  ILR1  reactivity is not  limited  to a  single 
allele of'SB. 
Analysis of associations between ILR 1 and individual alleles of DR and SB (Table 
I)  indicates  that  ILR1  binds  to all  donors' cells that  express SB2,  SB3, and  DR5. 
Although the data achieve statistical  significance only for SB2, they are consistent 
TABLE  I 
Population Study of the Correlation between  HLA-DR and SB and Binding of 
Monoclonal Antibody ILR1 
Antigen 
ILR 1 +  donors  ILR 1 -  donors 
(n =  31)*  (n ==  16)* 
Number  Percent  Number  Percent 
with  with  with  with 
antigen  antigen  antigen  antigen 
SB2~  12"  39  0  0 
SB3  8  26  0  0 
SB blank  6  19  1  6 
SB1  6  19  6  38 
SB4  12  39  11  69 
SB5  1  3  4  25 
DRI~  5  16  2  13 
DR2  11  35  6  38 
DR3  14  45  7  44 
DR4  7  23  2  13 
DR5  7  23  0  0 
DR7  5  16  6  38 
DR blank  1  3  0  0 
* Binding of ILR 1 to LCL was ascertained by FMF. 
The statistical significance (by chi square analysis) of the overall correlation 
between ILR1  and SB is highly significant  (P <  0.003)  but of the overall 
correlation between ILR1  and the six well-defined DR alleles is not signifi- 
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with the interpretation  that  ILR1  binds to all  DR5,  SB2,  and  SB3  molecules. The 
implication that ILR1  may bind to DR5 molecules is an interesting one, supported 
by other data  (C.  Hurley and S.  Shaw,  manuscript in preparation), but will not be 
documented  further  in  this  study  as  it  is  tangential  to  the  primary focus,  the  SB 
antigens.  More detailed  information on the association between SB  phenotype and 
ILRl-reactivity is represented  in  Fig.  1.  For ease of visualization, donors are repre- 
sented  on  either  side  of the  figure's axis of symmetry. Because  the  DR5  molecule 
appears to bind ILR 1, donors expressing DR5 are distinguished in the figure; however, 
none of the conclusions relating to SB are changed by inclusion or exclusion of those 
donors. All donors' cells expressing $B2 or SB3 also bind ILR1, suggesting that  the 
SB2  and  SB3  molecules  bind  ILR1.  The  remaining  25  donors'  cells  (which  are 
negative for SB2 and SB3) provide information on ILR1 binding to other alleles. Of 
these, the seven that express two defined SB alleles (SB1,4; SB1,5; and SB4,5) are the 
most informative; all of them fail to bind ILR1, suggesting that SB1, SB4, and SB5 
molecules lack the ILR 1-reactive epitope. This interpretation is also supported by the 
observation that most of the donors (8/12) that express SB 1 only (SB 1,1 or SB 1,blank) 
or SB4 only (SB4,4 or SB4,blank)  fail to bind ILR1. Thus all the data are consistent 
with the hypothesis that ILR1 binds to SB2 and SB3 molecules but not to SB1, SB4, 
or SB5 molecules. However, ILR1  also binds to six donors cells that lack SB2, SB3, 
and DR5; although not inconsistent with the foregoing hypothesis, ILR1 binding to 
those six donors' cells is not explained by it and requires  an additional  hypothesis. 
Either the ILR 1-reactive epitope is also present on some SB blank molecules, or there 
are other polymorphic molecules distinct from SB and DR that are also able to bind 
ILR1  (see Discussion). 
ILR1 Inhibits Proliferation of SB-specific but not DR-specific Primed T Cells. To test more 
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Fxc.  1.  Association between ILRl-reactivity and the SB phenotype of 47 donors' cells. Binding of 
ILRI to LCL was ascertained by FMF.  Cells  that  bind ILR1  (O), cells  that express DR5  (all  of 
which bind ILR1)  (HI) and  those that  do not bind ILR1  (O)  are  plotted  according to their SB 
antigen phenotype. Note that there is an axis of symmetry; for ease of visualization all donors are 
represented by a  symbol on either side of that axis, except  the donors typing for SB blank only, 
whose cells are on that axis. SHAW ET AL.  735 
directly the relevance of ILR 1-reactive molecules to the antigenic moieties defined by 
cellular typing, we tested the ability of ILR 1 to block SB-specific T  cell recognition. 
ILR 1 was added during secondary proliferative responses of primed T  cells responding 
to each of the five known SB antigens; responses to each of two DR antigens were 
included as controls (Table II). Addition of ILR 1 reduced the proliferative responses 
to two of the five SB antigens (SB2 and SB3) by at least 65%, but did not inhibit the 
proliferative responses to the other three SB antigens or to the two DR antigens tested. 
For both of the inhibited responses (SB2 and SB3) ILR1 binds only to the stimulator 
cells, not to the responding cells; thus, inhibition occurs by a  mechanism related to 
binding to  the  stimulator, not  the  responder cells.  Furthermore,  this  inhibition is 
antigen specific; although ILR 1 binds to the stimulator cells (from donor B 17)  that 
were used to stimulate both the DR2- and SB2-specific responses, it only inhibited 
the response to the SB2 antigen, not the DR2 antigen. 
The results of another representative inhibition experiment (Table III) strengthen 
the evidence that  ILR1  causes antigen-specific inhibition of T  cell proliferation by 
binding to the stimulator cell. As in the previous experiment, the conclusions are that: 
(a)  SB2- and SB3-specific responses are inhibited (by >70%), but SBI-, SB4-, SB5-, 
DRI-, and DR2-specific responses are not; (b) the inhibition operates at the level of 
the stimulator cell, as it occurs in combinations where stimulator but not responder 
cells bind ILR1; and (c)  this inhibition is antigen specific, as inhibition of the SB2- 
specific  response  to  cell  Y2  is  not  accompanied by  inhibition of the  SBl-specific 
response, for which Y2 was also used as a stimulator cell. This experiment differs from 
TABLE II 
Selective Inhibition of Secondary Lymphocyte Proliferation by the Monoclonal 
Antibody ILRI 
Stimulating  Percent  inhi- 
antigen  bition 
ILR 1 reactivity of 
cells from: 
Proliferation in the 
presence of antibody* 
Re-  Stimula-  Control:~  ILR 1  sponder  tor 
¢pm 
SB2  78%  -  +  103.6  22.6 
SB3  65%  -  +  46.3  16.1 
SB 1  5%  +  +  145.6  138.5 
SB4  10%  +  -  120.8  108.1 
SB5  8%  +  -  45.9  42.0 
DRI  13%  +  +  37.0  32.3 
DR2  0%  +  +  52.4  52.3 
The effect of addition of ILR 1 antibody on proliferative responses to SB and 
DR antigens. The combinations of donors used to generate the SB- and DR- 
specific primed cells are identical to those described previously (refer to refs. 
22, 23 in which the following  donors and priming combinations are described; 
the donor combination used to generate the SBl-primed cells used in this 
experiment was S1 l/H9, for SB2, F2/B17, for SB3, W7/M14, for SB4, S11/ 
PM1, for SB5, B17/F2, for DRI, H9/K4, and for DR2, FI/B17);  in each 
combination, the donors are identical for all HLA antigens (HLA-A, -B, 
[-C], -D, -DR, MB, MT, SB), except the one desired for priming. 
cpm expressed as cpm ×  10  -a. 
The control antibody was I2, a DR-specific anti-Ia monoclonal antibody 
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TABLE III 
Selective Inhibition of Secondary Lymphocyte Proliferation by the Monoclonal Antibody ILR1 
Stimulating 
antigen 
ILR1 reactivity of  Proliferation in presence of  Percent inhibition with:  cells from:  antibody:* 
Re-  Stimula- 
ILR1  L227  sponder  tor  Control:]:  ILRI  L227 
SB2  97  67  -  +  22.8  0.6  7.4 
SB3  71  45  +  +  33.7  9.8  18.5 
SB1  -13  89  +  +  35.2  39.9  3.9 
SB4  -10  ND  +  -  71.2  78.6  ND 
SB5  -37  56  +  -  56.8  77.8  24.7 
DR1  8  9  +  +  22.5  20.8  21.4 
DR2  -10  36  +  +  11.4  12.6  9.2 
The effect of addition of ILR1 antibody on proliferative responses to SB and DR antigens. As in Table 
II, the combinations of donors used to generate the SB- and DR-specific primed cells are identical to 
those described previously (22, 23; for reference to those citations the donor combination used to generate 
the SBl-primed cells was FB6/FB11, for SB2, W7/H9, for SB3, PM1/M14, for SB4, H9/M14, for SB5, 
H9/$11, for DR1, H9/K4, and for DR2, F1/B17); in each combination, the donors are identical for all 
HLA antigens (HLA-A, -B, [-C], -D, -DR, MB, MT,  SB), except the one desired for priming. The 
restimulating cells used in this experiment were Y2 (A26,32,B41,52,DR5,7,SB1,2) for SBI and SB2, E2 
(A3,B7,DR 1,4,SB3) for SB3, FC4 (A2,B7,DR2,SB4,5) for SB4 and SB5, L2 (A26,31,B  14,38,DR 1,4,SB2,4) 
for DR1, and M8 (A2,B8,DR2,3,SB3) for DR2. 
* cpm expressed as cpm ×  10  -a 
:~ The control antibody was I2. 
the previous one in three features of its design. First, the primed cells responding to 
each of the SB antigens were derived from a  different combination of responder and 
stimulator cells  (the second of the  two original donor combinations used  to  define 
these  antigens; see  22,  23);  therefore,  the inhibition seen for SB2- and SB3-specific 
primed cells can be attributed to their antigen specificity and not to other attributes 
of the donor combinations. Second, although the primed cells used in these experi- 
ments  were  generated  in  carefully  HLA-matched  donor  combinations and  have 
proven to  be  functionally monospecific in extensive proliferation studies, a  further 
precaution was taken to restrict the antigens recognized: the restimulating cells were 
chosen  to  be  HLA-mismatched with  the  primary  stimulating cell  for  all  but  the 
relevant  HLA  antigen  (e.g.,  for  SB2,  cells  from  donor  W7  [A1,2,  B7,8,  DR2,3, 
SB1,4],  which  had  been  primed  against  cells  from  donor  H9  [A1,2,  B7,8,  DR2,3, 
SB1,2]  and were  restimulated during this assay with cells from  donor Y2  [A26,32, 
B41,52,  DR5,7,  SB1,2]).  This further refinement of specificity of the  responding T 
cells did not alter the inhibition observed. Third, the possibility was considered that 
SB2-  and  SB3-specific  responses  might  be  nonspecifically more  susceptible  to  all 
inhibitory effects of monoclonal antibodies. As a control for this possibility, an anti-Ia 
monoclonal antibody (L227) was included that had been seen previously to partially 
inhibit T  cell proliferative responses to many specificities. The SB2- and SB3-specific 
proliferative responses  were  inhibited no  more  (and  perhaps  less)  by  monoclonal 
antibody L227 than were the proliferative responses specific for the other SB antigens. 
Genetic Mapping of ILR1 Reactivity in HLA-mutant Cell Lines. Previous studies both of 
recombinant families (24)  and of mutant cell lines (25)  indicated that HLA-DR and 
SB were encoded by separate loci in the human MHC. If ILR 1 recognizes an epitope 
on the same polypeptide as that detected by typing with cellular reagents, then the SHAW ET AL.  737 
genetics of ILR 1 reactivity should parallel those of the SB antigens defined by cellular 
typing.  This prediction  was explored using panels of mutant  cell lines that  had  been 
established  from  a  parent  LCL  expressing  the  HLA  haplotypes  (A*I,  B*8,  DR*3, 
SB* 4, GLO* 2), and  (A * 2, B* 5, DR* 1, SB* 2, and GLO* 1). Pilot studies indicate that 
an ILR 1-reactive molecule was encoded  by a  locus of the SB*2 haplotype,  as would 
be predicted from the studies described above. Of the mutant  lines available,  13 were 
chosen  that  had  lost  DR*I  from  one  HLA  haplotype  and  an  unknown  amount  of 
genetic material  centromeric  to DR* 1;  these lines were assayed  for expression  of the 
SB2  antigen  (as  detected  by  cellular  typing)  and  expression  of the  ILRl-reactive 
molecule (Table IV, Fig. 2). All seven independent lines that retained the SB2 antigen 
also retained  their ILRl-reaetivity  (type  1 and  type  3);  none  that  lost  SB2  (type  2) 
retained  ILR1  reactivity (P <  0.002,  two-tailed Fisher's exact test).  The  reactivity of 
ILR 1 with mutant  cell lines that  have lost expression of their DR 1 molecule encoded 
TABLE  IV 
Correlation between ILRI Reactivity and SB2 Expression on Mutant Cell 
Mutant line number 
Lines that Have Lost DR1 
Primed cells used to  Monoclonal Ab 
identify SB2*  reactivity 
SB2A  SB2B  ILR 1  I2 (DR) 
Parent  100"  100"  100~  100~ 
Type 1§ 
.51  52  52  150  109 
.52  39  58  155  599 
Type 2 
.77  7  6  1  82 
.78  8  6  1  131 
.113  9  7  1  128 
.116  3  4  1  192 
.120  6  4  0  187 
.127  19  7  1  229 
Type 3 
.81.3  125  85  184  0 
.137.1  143  117  273  0 
.82.4  62  83  189  0 
.84.5  98  98  200  0 
.101.1  101  83  167  0 
* The primed cell reagents used  to detect the SB2 antigens are identical to 
those previously described (22, 23); SB2A is generated by donor W7 anti-H9 
and  SB2B  by donor F2  anti-B17.  The proliferative data  are expressed  in 
terms of relative response,  i.e., responses  induced by the mutant stimulator 
cell compared with that  induced by the parent  line. Absolute cpm for the 
responses  was  29,750 for the SB2A-primed cells and  76,880 for the SB2B- 
primed cells. 
~: Antibody-binding data are expressed as percentage of the expression  on the 
parent line, as measured by FMF. The level of expression on the parent line 
was 5684 fluorescence units for I2 and 3964 fluorescence  units for ILR 1. 
§ See Fig. 2 for schematic representation showing different mutant  types.  All 
type 1 and type 2 mutants had lost expression of the A2 and B5 markers on 
that haplotype. Two of the type 2 mutants had lost GLO* 1 marker on that 
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GLO*I  SB2/ILR1  DR1 
Parent 
GLO*2  SB4  DR3 
GLO* 1  SB2/ILR 1  XXXXX 
Type 1 
GLO*2  SB4  DR3 
(GLO*I)  XXXXXXXXXXXXXXXXXX 
Type 2 
GLO*2  SB4  DR3 
GLO* 1  SB2/ILR 1  XXXXX 
Type 3 
XXXXXXXXXXXXXXXXXXXXXXXXXX 
Fro.  2.  Schematic of the HLA-DR/GLO segment of the  HLA haplotypes of the  HLA-deletion 
mutants analyzed.  For data, see Table IV. Of mutants that lost only part of one HLA haplotype, 
some had lost DR1 but not SB2 or ILR1  (type 1), whereas others had lost DR1 as well as SB2 and 
ILR1  (and  two had  lost  expression of GLO* 1)  (type  2).  Of mutants that  lost  the  entire  DR3 
haplotype and DR1, none had lost  SB2 or ILR1  (type 3). No mutants were identified which had 
lost SB2 but not ILRl-reactivity, or vice versa. 
on  the  SB*2-containing  haplotype  demonstrates  that  there  are  at  least  two  loci 
controlling expression of products that bind anti-Ia monoclonal antibodies.  Because 
the type 1 mutants had lost expression of genes in the segment HLA-A*2/HLA-B*5/ 
DR* 1, the retention of ILRl-reactivity in these mutants indicates that the gene that 
controls ILRl-detected polymorphism does not map between HLA-A and DR. 
These data are most dramatic for the DR-null mutant lines (Fig. 2, type 3), which 
have lost the entire opposite HLA haplotype. All five of these lines have lost reactivity 
with a monoclonal antibody detecting one class of Ia molecules (including HLA-DR) 
but retain reactivity with ILR1. Thus, the ILR1 reactive molecule that was previously 
shown to be distinct  from DR immunochemically (18,  26), is shown by these studies 
to be controlled by a locus distinct from those controlling HLA-DR. 
Discussion 
Three lines of evidence presented  in this report indicate  that  the ILR1  antibody 
binds  to some alleles of the  SB  molecule:  (a)  the polymorphism of ILRl-reactivity 
correlates  with  SB2  and  SB3  antigens  in  the  population;  (b)  T  cell  proliferative 
response to SB2 and SB3 are specifically inhibited by ILR1; and (c) the expression of 
ILR1  is exactly concordant  with the expression of SB2 in a  panel of HLA deletion 
mutant LCL. 
The studies of antibody inhibition  are taken to indicate that ILRl-reactive mole- 
cules  per se  are  responsible  for inducing  SB2-  and  SB3-specific  proliferation.  The 
simplest mechanism for explaining the observed inhibition is antibody-mediated steric 
hindrance of interaction between the T  cells and the SB molecule. This seems more 
plausible than other possible mechanisms, such as one by which ILR1 could induce 
suppression.  This is  conceivable, but  no experimental evidence has been  found  for 
suppression  in  this system (S.  Shaw,  unpublished  observations), and this  inhibition 
differs in two important ways from the suppression-induction previously reported (35) 
for  anti-Ia  antibodies:  it  is  antigen-specific,  and  the  inhibition  is  observed  in  a 
secondary rather than a  primary response. It is also possible that  the ILRl-reactive 
molecule is distinct from SB but has a unique steric relationship to SB which accounts 
for  the  inhibition.  This  is  an  unattractive  hypothesis  as  this  postulated  molecule SHAW ET AL.  739 
would also have to (a) have a polymorphism in the population indistinguishable from 
that of SB (to explain the population association); (b) be controlled by a locus located 
close to SB  (to explain the mutant data);  and  (¢)  have a  unique relationship on the 
cell  surface  with  SB2  and  SB3  but  not,  for example,  with  SB1  or  DR2  (because 
concurrent responses to those antigens on the same cell are not inhibited). 
Thus, several lines of evidence indicate that ILR 1 binds to an epitope on the SB2 
and the SB3 molecules. In addition,  the results of population studies  in this report, 
when  combined  with  those  previously  published  (18),  demonstrate  a  correlation 
between  DR5  and  ILR1  reactivity  (P  <  0.004,  Fisher's  exact  test)  that  retains 
statistical  significance  (P <  0.05)  even after correction  for the number of antigens 
analyzed.  Several other lines of evidence support the conclusion that ILR1 binds to 
DR5 but to no other allotypic forms of HLA-DR (C. Hurley and S. Shaw, manuscript 
in  preparation).  Thus,  ILR1  appears  to  bind  SB2,  SB3,  and  DRS.  There  are  six 
donors,  however  (Fig.  1),  whose cells bind  ILR1  despite  the  fact that  they do  ~  not 
express SB2,  SB3, and DRS. This could indicate that ILR1  binds not only to some 
DR molecules and some SB  molecules, but  also to some products of another gene. 
There is no need to postulate involvement of a  third gene product, though;  because 
all six donors with unexplained ILR1 reactivity have at least one undefined SB allele, 
they may express another allotypic form of the SB  molecule  (e.g.,  a  future  SB6  or 
SB7)  that also binds ILR1. This hypothesis is consistent with emerging evidence for 
a  new SB allele that is crossreactive with SB4 but that, unlike SB4, binds ILR1  (S. 
Shaw, unpublished observations). 
Thus,  the  ILRl-binding  epitope  appears  to  be  shared  by  some  SB  and  DR 
molecules.  Monoclonal  antibodies  have identified  polymorphic epitopes shared  by 
distinct but homologous murine Ia molecules: IA and IE (36). The sharing of such an 
epitope between  DR  and  SB  would  appear to reflect  extensive homology between 
these two distinct gene products. Another study of monoclonal antibody inhibition of 
proliferation also suggests that SB and DR share serologically defined determinants, a 
In  that  study,  some  monoclonal  antibodies  specific  for monomorphic  epitopes  on 
human Ia molecules were able to inhibit proliferation of T  cells specific for all HLA- 
DR and SB determinants tested. Data from these two studies are consistent with the 
hypothesis proposed previously (22)  that SB and DR genes are derived from duplica- 
tion of an ancestral gene(s). 
Although ILR 1 is not exclusively SB specific, data indicate that ILR 1 can be used 
to identify SB molecules in informative donors; i.e., that are positive for SB2 or SB3 
but negative for DRS.  Such an approach is subject to the caveat that ILR1, like all 
other monoclonal antibodies, may also bind other unidentified gene products. Previous 
immunochemical studies  (18,  26)  on  cells  now  known  to  be informative for ILR1 
binding  to  SB  indicate  that  ILR1  precipitates  a  glycoprotein  composed  of  two 
polypeptide chains with molecular weights of 29,000 and 34,000.  Preliminary results 
of further  structural  studies  of the  ILRl-reactive molecule  indicate  that  it  has an 
alpha chain amino acid sequence that is similar or identical  to the HLA-DR alpha 
chain, but has a  novel beta chain (C. Hurley and J. D. Capra, personal communica- 
tion).  These  results  support  the  hypothesis  that  SB  molecules  are  typical  Ia-like 
a G. Pawalec, S. Shaw, A. Ziegler,  C. Muller, and P. Wernet. Differential inhibition of HLA-DR- or SB- 
directed secondary lymphoproliferative responses with monoclonal antibodies detecting human  Ia-like 
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molecules, as proposed previously (22) on the basis of the function of SB determinants 
in allogeneic T  cell responses and their tissue distribution. The only approach that 
can demonstrate with certainty that  the functions of the SB antigens are served by 
epitopes on Ia-like molecules is the direct demonstration of SB-specific responses to 
those molecules after their isolation and purification. 
The  availability  of a  serological  reagent  to  define  SB2  and  SB3  antigens  in 
informative  donors  allows  refinement  of  the  previous  conclusions  on  the  tissue 
distribution of the SB determinants implied in studies of target cell susceptibility to 
cell-mediated lysis (22). In such donors, the ILRl-reaetive molecule was serologically 
identifiable on peripheral B cells, macrophages, and particularly well on B cell LCL, 
but not on resting T  cells (26). ILR1 studies resolve an uncertainty of cellular studies 
by demonstrating that activated T  cells express SB antigen, as they do DR antigens 
(37, 38), 
Studies on the mutant cell lines corroborate the close genetic relationship between 
ILR1 reactivity and SB expression--i.e., that, so far, they are indistinguishable. Those 
studies  also  provide direct  serologic confirmation that  there are  two  HLA regions 
centromeric to HLA-B that  control expression of Ia-like molecules. This had  been 
suggested by family studies of alloantisera  (7,  21)  and can be inferred from family 
studies using cellular typing techniques (24, 27, 28). Mapping of the loci controlling 
expression  of these  Ia-like  antigens  is  facilitated  by  the  mutants.  Because  ILR1 
reactivity is preserved in mutants that have lost expression of genes in the HLA-A/DR 
segment (the type 1 mutants), the gene controlling its polymorphism does not map to 
that region. Because polymorphism of ILR1 has been previously mapped to the HLA- 
DR side of a HLA-B/DR recombination (18), ILR 1 reactivity appears to be controlled 
by a least one gene that maps centromeric to HLA-DR.  Thus, in the region bounded 
by  HLA-B  and  GLO  (often  referred  to  by  the  vague  term  D  region),  there  is  a 
subregion  toward  HLA-B  including  a  locus  that  controls  expression  of HLA-DR 
(defined serologically by alloantisera and monoclonal antibodies L243 and I2), and 
a subregion toward GLO that includes a locus that controls expression of SB (defined 
serologically by monoclonal antibody ILR1). Mutagenesis of LCL promises to con- 
tinue as a  powerful tool in  dissecting out  the genetics of HLA, as there is already 
preliminary  evidence  for  serological  and  cellular  definition  of products  of genes 
mapping  to  a  third  subregion  of this  genetic  segment  (HLA-B/GLO),  which  are 
expressed on some but not other mutants (R. Duquesnoy, F. H. Bach, and R. DeMars, 
unpublished observations). 
The existence of this antibody, which detects the SB molecule, resolves uncertainty 
as to whether the SB antigens are readily identifiable serologically. Concurrent with 
these studies, evidence is emerging that  alloantisera can be identified that  bind to 
HLA  determinants  highly  associated  in  the  population  with  SB  polymorphism.  4 
Development of serological  tools  that  identify the  SB  gene  product  will  facilitate 
further studies of the biological relevance of this recently discovered human Ia-like 
gene product. 
Summary 
The  secondary  B  cell  (SB)  antigens  are  polymorphic  HLA-linked  antigens  on 
human B cells and macrophages that are identified by primed T  cell responses but 
4 A. Van Leeuwen, A. Termijtelen, S. Shaw, and J. j. Van Rood. The recognition of a  polymorphic 
monocyte antigen in HLA. Manuscript submitted for publication. SHAW ET AL.  741 
are genetically distinct  from the HLA-DR, MB, and MT antigens.  Serologic identi- 
fication  of the  SB  molecule,  using  the  rnonoclonal  antibody  ILR1,  now  makes  it 
possible to correlate the function of these determinants  in human T  cell recognition 
with  an  Ia-like  molecular  structure  and  a  genetic  locus  that  marks  a  new  HLA 
subregion.  Three  lines  of evidence  indicate  that  the  ILR1  molecule  identifies  an 
epitope on some alleles  of the SB gene:  (a)  the polymorphism of ILRl-reactivity in 
the population correlates with SB2, SB3;  (b)  T  cell proliferative response to SB2 and 
SB3 are specifically inhibited  by ILR 1; and (c)  ILR 1 reactivity is exactly concordant 
with  the expression  of SB2 in a  panel  of HLA-deletion mutant  lymphoblastoid cell 
lines.  Together with previous studies,  these results indicate that  the SB antigens  are 
on Ia-like molecules. Furthermore,  the serologic studies of HLA-deletion mutant cell 
lines demonstrate that there are two HLA regions centromeric to HLA-B controlling 
expression  of Ia-like molecules:  a  region  toward  HLA-B that  controls expression  of 
HLA-DR, and a  region toward GLO that controls expression of SB. 
We thank  the staff of the NIH blood bank  for leukapheresing  donors,  S.  Sharrow and  D. 
Stephany for performing the FMF analysis, C. Chang and R. Rudersdorf for production of the 
mutant LCL, the staff of the Blood Center of Southeastern Wisconsin for serotyping donors' 
cells, and Dr. W. Terry, Dr. G. Shearer, Dr. B. Biddison, Dr. D. Sachs, and Dr. D. Singer for 
valuable discussion. 
Received  for publication 27 April 1982. 
References 
1.  Uhr, J. W., J. D. Capra, E. S. Vitetta, and R. G. Cook. 1979. Organization of the immune 
response genes.  Both subunits of murine I-A and I-E/C molecules are encoded within the 
I region. Science (Wash.  D. C.). 206:292. 
2.  Benacerraf,  B.  1981. Role of MHC gene products in immune regulation.  Science (Wash. 
D. C.). 212:1229. 
3.  Barnstable,  L. J., and E. A. Jones.  1978. Isolation, structure and genetics of the HLA-A, 
-B,-D, and -DRw (Ia) antigens. Br. Med.  J. 32:241. 
4.  Amos, D. B., and D. D. Kostyu. 1980. HLA--a central immunological agency in man. Adv. 
Hum. Genet. 10:137. 
5.  Van Rood, J. j., R. R. P. De Vries, and B. A. Bradley.  1981. Genetics and biology of the 
HLA system.  In  The  Role  of the  MHC  in  Immunology. M.  E.  Dorf,  editor.  Garland 
Publishing, Inc., New York. 59-113. 
6.  Duquesnoy, R. J., and M. Marrari.  1980. MB system. In Histocompatibility Testing 1980. 
P. I. Terasaki, editor. UCLA Tissue Typing Laboratory, Los Angeles.  552-555. 
7.  Park,  M.  S.,  and  P.  I. Terasaki.  1980. Second DR  locus.  In  Histocompatibility Testing 
1980. P. I. Terasaki, editor. UCLA Tissue Typing Laboratory, Los Angeles. 578-582. 
8.  Park, M. S., P. I. Terasaki,  S. Nakata, and D. Aoki.  1980. Supertypic groups: DR, MT1, 
MT2, and MT3. In Histocompatibility Testing 1980. P. I. Terasaki, editor. UCLA Tissue 
Typing Laboratory, Los Angeles.  854-857. 
9.  Katagira, M., H. Ikeda, N. Maruyama, J. Moriuchi, A. Wakisaka, S. Kimura, M. Aizawa, 
and  K.  Itakura.  1979. Evidence  for two  B  cell  alloantigen  loci  in  the  HLA-D region. 
hnmunogenetics. 9:335. 
10.  Tosi, R., N. Tanigaki,  D. Centis,  G.  B. Ferrara,  and D.  Pressman.  1978. Immunological 
dissection of human Ia molecules.J. Exp. Med. 148:1592. 
11.  Corte, G., F. Calabi, G. Domiani, A. Bargellesi,  R. Tosi, and R. Sorrentino.  1981. Human 
Ia molecules carrying DC1  determinants differ in both alpha and beta subunits  from Ia 742  SEROLOGIC  DEFINITION OF SECONDARY  B CELL  ANTIGENS 
molecules carrying DR determinants. Nature (Lord.). 292:537. 
12.  Shackelford, D. A., D. L. Mann, J. J. Van Rood, G. B. Ferrara, and J. L. Strominger. 1981. 
Human B-cell alloantigens DC1, MT1, and LB12 are identical to each other but distinct 
from the HLA-DR antigen. Proc. Natl.  Acad. Sci. U. S. A.  78:4566. 
13.  Shackelford, D. A., and J. L. Strominger. 1980. Demonstration of structural polymorphism 
among HLA-DR light chains by two-dimensional electrophoresis.J. Exp. Med.  151:144. 
14.  Charron,  D. J.,  and  H.  O.  McDevitt.  1979.  Analysis of the  HLA-D  region-associated 
molecules with monoclonal antibody. Proc. Natl.  Acad. Sci. U. S. A. 76:6567. 
15.  Markert,  M.  L.,  and  P.  Cresswell.  1980.  Polymorphism of human  B-cell alloantigens: 
evidence for three loci within the HLA system. Proc. Natl. Acad. Sci. U. S. A. 77:6106. 
16.  Quaranta,  V.,  M.  A. Pellegrino, and  S.  Ferrone.  1981. Serologic and  immunochemical 
characterization  of the  specificity of four  monoclonal  antibodies  to  distinct  antigenic 
determinants expressed on subpopulations of human Ia-like antigens. J. Immunol.  126:548. 
17.  Goyert, S. M., andJ. Silver. 1981. Isolation of I-A subregion like molecules from subhuman 
primates and man. Nature (Lord.). 294:266. 
18.  Nadler, L. M., P. Stashenko, R. Hardy, K. J. Tomaselli, E. J. Yunis, S. F. Schlossman, and 
J. M. Pesando.  1981. Monoclonal antibody identifies a new Ia-like (p29,34)  polymorphic 
system linked to the HLA-D/DR region. Nature  (Lord.). 290:591. 
19.  Kratzin, H., C.-Y. Yang, H. Gotz, D. Pauly, S. Kolbel, G. Egert, F. P. Thines, P. Wernet, 
P. Altevogt, and N. Hilschman.  1981. Primarstruktur menschlicher Histokompatibilitaet- 
santigen der klasse II. I. Mitteilung: aminosaeuresequenz der N-terminalen 198 reste der 
beta-kette des HLA-Dw2,2; DR2,2-alloantigens. Hoppe-Seyler's Z. Physiol.  Chem. 362:1665. 
20.  Duquesnoy, R. J., A. Zeevi, M. Marrari, and K. Halim.  1982. Immunogenetic analysis of 
the  HLA-D region: serological and  cellular detection of the  MB  system.  Clin.  Immunol. 
Immunopathol. In press. 
21.  Van Leeuwen, A., H. Festenstein, J. D'Amaro, C. Naverette, J. Awad, and J. J. Van Rood. 
1980. A new B cell locus defined by a recombinant family. In Histocompatibility Testing 
1980. P. I. Terasaki, editor. UCLA Tissue Typing Laboratory, Los Angeles. 853. 
22.  Shaw, S., A. H. Johnson, and G. M. Shearer. 1980. Evidence for a new segregant series of 
B  cell antigens  that  are  encoded  in  the  HLA-D  region  and  that  stimulate secondary 
allogeneic proliferative and cytotoxic responses.J. Exp. Med.  152:565. 
23.  Shaw, S., R. J. Duquesnoy, and P. L. Smith.  1981. Population studies of the HLA-linked 
SB antigens. Immunogenetics. 14:153. 
24.  Shaw, S., P. Kavathas, M. S. Pollack, D. Charmot, and C. Mawas.  1981. Family studies 
define a  new  histocompatibility locus, SB,  between  HLA-DR and GLO.  Nature  (Lond.). 
293:745. 
25.  Kavathas, P., R. DeMars, F. H. Bach, and S. Shaw.  1981. SB: a new HLA-linked human 
histocompatibility gene defined using HLA-mutant cell lines. Nature  (Lord.). 293:747. 
26.  Nadler, L. M., P. Stashenko, R. Hardy, J. M. Pesando, E. J. Yunis, and S. F. Schlossman. 
1981.  Monoclonal antibodies defining serologically distinct  HLA-D/DR  related Ia-like 
antigens in man. Hum. Immunol.  1:77. 
27.  Mawas, C., D. Charmot, M. Sivy, P. Mercier, M. L. North, and G. Hauptmann.  1978. A 
weak human MLR locus mapping at the right of a crossing over between HLA-D,Bf and 
GLO.J. Immunogenet. 5:583. 
28.  Mawas, C., D. Charmot, and P. Mercier. 1980. Split of HLA-D into two regions alpha and 
beta by a  recombination between  HLA-D and GLO.  I.  Study in  a  family and  primed 
lymphocyte typing for determinants coded by the beta region. Tissue Antigens.  15:458. 
29.  Lampson, L. A., and R. Levy. 1980. Two populations of Ia-like molecules on a human B 
cell line.J. Immunol.  125:293. 
30.  Sharrow, S. O., K. Ozato, and D. H. Sachs. 1980. Phenotypic expression of I-A and I-E/C 
subregion determinants on murine thymocytes. J. Immunol.  125:2263. SHAW ET AL.  743 
31.  Mathieson, B.J., S. O. Sharrow, P. S. Campbell, and R. Asofsky. 1979. An Lyt differentiated 
subpopulation of thymocytes detected by flow microfluorometry. Nature (Lond.). 277:478. 
32.  Bird, A. G., S. M. McLachlan, and S. Britton.  1981. Cyclosporin A promotes spontaneous 
outgrowth in vitro of Epstein-Barr virus induced B-cell lines. Nature (Lond.). 289:300. 
33.  Kavathas, P., F. H. Bach, and R. DeMars.  1980. Gamma ray-induced loss of expression of 
HLA and glyoxylase I alleles in lymphoblastoid cells. Proc. Natl. Acad. Sci. U. S. A. 77:4251. 
34.  Shows, T. B.  1979. Conventions on genetic nomenclature. Cytogenet. Cell Genet. 25:96. 
35.  Broder, S., D. L. Mann, and T. A. Waldmann.  1980. Participation of suppressor T cells in 
the immunosuppressive activity of a  heteroantiserum to human Ia-like antigens (p23,30). 
J. Exp.  Med.  151:257. 
36.  Pierres, M., C. Devaux, M. Dosseto, and S. Marehetto. 1981. Clonal analysis of B- and T- 
cell responses to Ia antigens. I. Topology of epitope regions on  I-A  k and  I-E  k molecules 
analyzed with 35 monoclonal antibodies. Immunogenetics. 14:481. 
37.  Ko, H.-S., S. M. Fu, R.J. Winchester, D. T. Y. Yu, and H. G. Kunkel. 1979. Ia determinant 
on stimulated human lymphocytes. Occurence on mitogen- and antigen-activated T  cells. 
J. Exp.  Med.  150.246. 
38.  Reinherz, E. L., P. C. Kung, J. M. Pesando, J. Ritz, G. Goldstein, and S. F. Schlossman. 
1979. Ia determinants on human T cell subsets defined by monoclonal antibody. Activation 
stimuli required for expression.J. Exp. Med.  150:1472. 